奥曲肽治疗32例老年人中晚期肝癌临床疗效观察

EFFECTS OF OCTREOTIDE IN ELDERLY PATIENTS WITH ADVANCED PRIMARY HEPATIC CANCER

目的 探讨奥曲肽治疗老年中晚期原发性肝癌的临床疗效和安全性。方法 采用随机、对照方法,将65例老年中晚期肝癌分为奥曲肽组32例,对照组33例。按WHO癌症治疗客观疗效评定。结果 2组近期疗效无显著差异,但治疗组中位生存期、6个月生存率分别为(11.61±3.50)月、61.54%,远高于对照组的(5.64±1.44)月、32%(P<0.05),且治疗组生存质量有明显改善。结论 奥曲肽能延长中晚期肝癌患者临床生存期,提高生活质量,副反应轻。

Objective: To evaluate the effects and safety of administration of octreotide in elderly patients with advanced primary hepatic cancer (PHC). Methods: Sixty-five PHCs were divided randomly into two groups: octreotide group(n=32) and control group(n=33). The effects of treatment were assessed with the WHO criteria (CR,PR,NC,PD).Results:5 PHCs of octreotide group were PR while no CR or PR observed in control group(P<0.05). Side effects were observed in 3 PHCs of octreotide group (3/32) while none in control group.Conclusion: Octreotide treatment is beneficial on prognosis of advanced PHC in elderly patients and with light side effects.